CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts

129Citations
Citations of this article
106Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

CD44 is a marker of tumour-initiating cells and is upregulated in invasive breast carcinoma; however, its role in the cancer progression is unknown. Here, we show that antibody-mediated CD44-targeting in human breast cancer xenografts (HBCx) significantly reduces tumour growth and that this effect is associated to induction of growth-inhibiting factors. Moreover, treatment with this antibody prevents tumour relapse after chemotherapy-induced remission in a basal-like HBCx. © 2009 Cancer Research.

Author supplied keywords

Cite

CITATION STYLE

APA

Marangoni, E., Lecomte, N., Durand, L., De Pinieux, G., Decaudin, D., Chomienne, C., … Poupon, M. F. (2009). CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. British Journal of Cancer, 100(6), 918–922. https://doi.org/10.1038/sj.bjc.6604953

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free